| Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T Cells to protect tumour cells MA Lakins, E Ghorani, H Munir, CP Martins, JD Shields Nature communications 9 (1), 948, 2018 | 477 | 2018 |
| FS222, a CD137/PD-L1 tetravalent bispecific antibody, exhibits low toxicity and antitumor activity in colorectal cancer models MA Lakins, A Koers, R Giambalvo, J Munoz-Olaya, R Hughes, ... Clinical Cancer Research 26 (15), 4154-4167, 2020 | 47 | 2020 |
| Exploiting advances in imaging technology to study biofilms by applying multiphoton laser scanning microscopy as an imaging and manipulation tool MA Lakins, JL Marrison, PJ O’TOOLE, MW Van der Woude Journal of microscopy 235 (2), 128-137, 2009 | 14 | 2009 |
| Stromal immunology BMJ Owens, MA Lakins Springer, 2018 | 4 | 2018 |
| Antibody molecules that bind pd-l1 and cd137 M Lakins, J Munoz-Olaya, F Wollerton, S Batey, M Tuna, A Koers US Patent App. 17/259,791, 2022 | 2 | 2022 |
| Antibody molecules F Wollerton, M Lakins, M Wydro, S Surade, M Dyson US Patent App. 17/259,642, 2021 | 2 | 2021 |
| Fc binding fragments comprising cd137 antigne binding side M Lakins, J Munoz-Olaya, S Pechouckova, M Tuna | 2 | 2020 |
| 573 FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the antitumor activity of anti-PD-1 in preclinical studies M Lakins, W Liao, E McConnell, Q Kaka, J Ofoedu, C Gradinaru, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A602-A602, 2021 | 1 | 2021 |
| ANTIBODY MOLECULES THAT BIND TO PD-L1 AND CD137 M Lakins, J Munoz-Olaya, F Wollerton, S Batey, M Tuna, A Koers | 1 | 2021 |
| Clustering CD137 via cell-expressed PD-L1 crosslinking avoided Fc-mediated agonism and resulted in safe and potent conditional lymphocyte activation MA Lakins, A Koers, R Giambalvo, R Hughes, S Marshall, M Wydro, ... Cancer Res. 80, 4547, 2020 | 1 | 2020 |
| FS222 mAb2, a bispecific conditional agonist antibody targeting CD137 and PD-L1, induces potent lymphocyte activation and has a favorable safety profile MA Lakins, A Koers, JM Olaya, R Giambalvo, D Jones, S Pechouckova, ... Cancer Research 79 (13_Supplement), 1540-1540, 2019 | 1 | 2019 |
| The role of stroma microenvironments in prostate cancer cell migration and metastasis M Lakins University of York, 2012 | 1 | 2012 |
| 173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors GADV Oria, E Garralda, VM Garcia, I Melero, IV Ruiz, A Indacochea, ... Immuno-Oncology and Technology 16, 2022 | | 2022 |
| 1069 OX40/CD137 dual agonism potentiates anti-tumour immunity by driving functional reprogramming and instability of regulatory T (Treg) cells C Imianowski, P Kuo, E Poon, M Lakins, M Morrow, R Roychoudhuri Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 165TiP A first-in-human phase I study of FS222, a CD137/PD-L1 tetravalent bispecific antibody, in patients with advanced malignancies E Garralda, I Melero, G de Velasco, V Moreno, HK Oberoi, C Shepherd, ... Annals of Oncology 32, S1454, 2021 | | 2021 |
| FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, is designed for optimal CD137 interactions resulting in potent T cell activation without toxicity MA Lakins, J Munoz-Olaya, C Veyssier, D Jones, E Goodman, Q Kaka, ... Cancer Research 81 (13_Supplement), 1864-1864, 2021 | | 2021 |
| FC BINDING FRAGMENTS THAT UNDERSTAND AN ANTIGEN BINDING SITE CD137 M Lakins, J Munoz-Olaya, S Pechouckova, M Tuna | | 2021 |
| Antibody molecules F WOLLERTON, M LAKINS, M WYDRO, S SURADE, M Dyson | | 2020 |
| Optimising TNFRSF agonism and checkpoint blockade with a novel CD137/PD-L1 bispecific antibody MA Lakins, J Munoz-Olaya, D Jones, R Giambalvo, C Hall, A Knudsen, ... Annals of Oncology 29, x30, 2018 | | 2018 |
| Stromal Immunology Preface BMJ Owens, MA Lakins STROMAL IMMUNOLOGY 1060, V-VI, 2018 | | 2018 |
